Patents by Inventor Ordan Lehmann

Ordan Lehmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OVEREXPRESSION OF FOXC1 TO TREAT CORNEAL VASCULARIZATION
    Publication number: 20210238241
    Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 5, 2021
    Applicants: Northwestern University, The Governors of the University of Alberta
    Inventors: Tsutomu Kume, Ordan Lehmann
  • Overexpression of FOXC1 to treat corneal vascularization
    Patent number: 11001618
    Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: May 11, 2021
    Assignees: Northwestern University, The Governors of the University of Alberta
    Inventors: Tsutomu Kume, Ordan Lehmann
  • OVEREXPRESSION OF FOXC1 TO TREAT CORNEAL VASCULARIZATION
    Publication number: 20190270782
    Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.
    Type: Application
    Filed: February 18, 2019
    Publication date: September 5, 2019
    Applicants: Northwestern University, The Governors of the University of Alberta
    Inventors: Tsutomu Kume, Ordan Lehmann